Analysts at Zacks Small Cap have recently revised their earnings per share (EPS) estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), signaling a potentially challenging financial outlook for the biotechnology firm. This development, detailed in a research note issued on Monday, July 28th, highlights the dynamic nature of financial projections within the competitive pharmaceutical sector.
Specifically, Zacks Small Cap analyst M. Marin now anticipates Oramed Pharmaceuticals will report earnings of ($0.04) per share for the second quarter of 2025. This figure represents a notable reduction from their previous forecast of ($0.01), underscoring a more conservative view on the company’s near-term profitability. The broader consensus estimate for Oramed Pharmaceuticals’ current full-year earnings also stands at ($0.03) per share, reflecting a general agreement among analysts regarding the revised outlook.
The adjustments extend beyond the immediate quarter, with Zacks Small Cap issuing revised EPS estimates for subsequent periods. The third quarter of 2025 is now projected at ($0.04) EPS, followed by ($0.08) EPS for the fourth quarter of 2025. For the entirety of fiscal year 2025, the earnings forecast has been lowered to ($0.34) EPS, emphasizing a sustained period of anticipated financial headwinds for the biotechnology earnings of Oramed Pharmaceuticals.
These updated projections follow Oramed Pharmaceuticals’ most recent quarterly earnings report on Thursday, May 15th, where the company posted ($0.19) EPS. This result significantly missed the consensus estimate of ($0.03) by ($0.16), indicating a performance shortfall that likely contributed to the analysts’ downward revisions. Despite the earnings miss, the firm did report revenue of $2.00 million for the quarter.
In terms of stock performance, Oramed Pharmaceuticals, a key player in the pharmaceutical industry, opened at $2.15 on Thursday, holding a market capitalization of $87.83 million. The company’s price-to-earnings ratio stands at -4.89, with a beta of 1.59. Over the past year, the ORMP stock has traded within a range of $1.82 (1-year low) to $3.09 (1-year high), with recent trading activity showing a 50-day simple moving average of $2.18 and a 200-day simple moving average of $2.23.
Institutional investor activity provides further insight into the investment analysis surrounding Oramed Pharmaceuticals. Several prominent firms have recently adjusted their holdings, with Wealth Enhancement Advisory Services LLC increasing its stake by 36.2% in the second quarter. Jane Street Group LLC and N.E.W. Advisory Services LLC also significantly raised their positions. Notably, BML Capital Management LLC boosted its holdings by 14.3%, acquiring an additional 376,841 shares, bringing its total to over 3 million shares valued at $6.46 million, highlighting significant investment confidence.
Oramed Pharmaceuticals Inc. is dedicated to the research and development of innovative pharmaceutical solutions, primarily focusing on diabetes treatment. Their flagship product, ORMD-0801, is an oral insulin capsule currently in phase III clinical trials for individuals with diabetes. This groundbreaking oral insulin technology aims to revolutionize diabetes management, offering a less invasive alternative to traditional injectable insulin.
Beyond its advanced diabetes treatment, ORMD-0801 is also undergoing phase II clinical trials for the treatment of non-alcoholic steatohepatitis. Additionally, the company’s portfolio includes ORA-D-013-1 and ORA-D-013-2, both of which have successfully completed phase II clinical trials for the treatment of type 2 diabetes, reinforcing Oramed Pharmaceuticals’ commitment to addressing significant health challenges through advanced biotechnology.
Leave a Reply